GGrantIndex
← Leaderboards

Robert Irving Lehrer

University Of California Los Angeles

$5,468,942
Attributed
$5,853,942
Total exposure
11
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $547.1K · FY200510
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10

Funding mix

By agency

NIH$9,227,403 · 13

By mechanism

R01$3,500,055 · 5
P01$3,235,470 · 2
R37$1,119,620 · 1
R21$776,882 · 2
S10$595,376 · 3

Top collaborators

Most similar at University Of California Los Angeles

Same institution · by research overlap

Others in their field

Top investigators on “Peptides

Research focus

PeptidesAntibioticsProtein Structure FunctionSexually Transmitted DiseasesProtein PurificationLeukocytesDefensinsTopical Drug ApplicationHost Organism InteractionDisease /Disorder Prevention /ControlDrug Design /Synthesis /ProductionLaboratory MousePolymerase Chain ReactionCandida AlbicansHuman SubjectDrug Screening /EvaluationClinical ResearchNeutrophilPeptide Chemical SynthesisHuman TissueHiv InfectionsEscherichia ColiBinding (Molecular Function)Endopeptidases

Grant awards (29)

Retrocyclins: Cyclic mini-defensins that inactivate anthrax toxins$385,000
R01 · FY2010 · AI · contact PI
Retrocyclins: Cyclic mini-defensins that inactivate anthrax toxins$385,000
R01 · FY2009 · AI · contact PI
Theta-defensins Novel HIV-1 Uptake Inhibitors$256,365
R01 · FY2007 · AI · contact PI
Retrocyclin reinforcement of pulmonary defenses against viral aerosols$112,090
R21 · FY2007 · AI · contact PI
Retrocyclin reinforcement of pulmonary defenses against viral aerosols$283,125
R21 · FY2006 · AI · contact PI
Theta-defensins Novel HIV-1 Uptake Inhibitors$264,022
R01 · FY2006 · AI · contact PI
Theta-defensins Novel HIV-1 Uptake Inhibitors$270,083
R01 · FY2005 · AI
Biacore 3000 SPR Instrument$297,688
S10 · FY2004 · RR
BIACORE 3000 SPR INSTRUMENT: AIDS$186,055
S10 · FY2004 · RR
BIACORE 3000 SPR INSTRUMENT: INFECTIOUS DISEASE$111,633
S10 · FY2004 · RR
TOPICAL PROTEGRINS TO PREVENT STDS &HIV INFECTION$814,680
P01 · FY2003 · AI
Theta-defensins: Novel HIV-1 Uptake Inhibitors$381,667
R21 · FY2003 · AI
ALPHA HELICAL CATHELICIDINS AND HOST DEFENSE$251,526
R01 · FY2003 · AI
TOPICAL PROTEGRINS TO PREVENT STDS &HIV INFECTION$740,923
P01 · FY2002 · AI
DEFENSINS--ANTIMICROBIAL PEPTIDES OF HUMAN NEUTROPHILS$384,291
R37 · FY2002 · AI
ALPHA HELICAL CATHELICIDINS AND HOST DEFENSE$244,953
R01 · FY2002 · AI
PROTEGRIN DESIGN$0
P01 · FY2002 · AI
TOPICAL PROTEGRINS TO PREVENT STDS &HIV INFECTION$770,122
P01 · FY2001 · AI
DEFENSINS--ANTIMICROBIAL PEPTIDES OF HUMAN NEUTROPHILS$373,098
R37 · FY2001 · AI
ALTRUINS, NATURAL ANTIBIOTICS OF THE MALE GENITAL TRACT$287,609
R01 · FY2001 · AI
ALPHA HELICAL CATHELICIDINS AND HOST DEFENSE$237,814
R01 · FY2001 · AI
STRUCTURE/FUNCTIONS OF HUMAN TEAR LIPOPHILIN$206,792
R01 · FY2001 · EY
PROTEGRIN DESIGN$0
P01 · FY2001 · AI
TOPICAL PROTEGRINS TO PREVENT STDS &HIV INFECTION$750,048
P01 · FY2000 · AI
DEFENSINS--ANTIMICROBIAL PEPTIDES OF HUMAN NEUTROPHILS$362,231
R37 · FY2000 · AI
ALTRUINS, NATURAL ANTIBIOTICS OF THE MALE GENITAL TRACT$279,230
R01 · FY2000 · AI
ALPHA HELICAL CATHELICIDINS AND HOST DEFENSE$230,891
R01 · FY2000 · AI
STRUCTURE/FUNCTIONS OF HUMAN TEAR LIPOPHILIN$200,770
R01 · FY2000 · EY
PROTEGRIN DESIGN$159,697
P01 · FY2000 · AI